Explore ›
Finding
Finding
null
Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, using the pre-specified modified ITT analysis (dropouts = smokers).
| Effect size | 36% vs 31%, Chi2=0.49 |
| Follow-up | 12 weeks |
| Comparator | Placebo + transdermal NRT (21/14/7mg taper) + weekly group CBT (13 sessions) |
| Effect summary | null; 36% vs 31%, Chi2=0.49 |
| Effect modifiers | [{"modifier": "Current vs past UDD status", "interaction_p": "", "direction": "null", "stratum_details": "Current UDD: bupropion 33% (15/45) vs placebo 31% (14/45), Chi2=0.05, ns. Past UDD: bupropion 39% (20/52) vs placebo 32% (18/57), Chi2=0.57, ns.", "plain_language": "Whether depression was active or in the past at enrollment didn't change bupropion's effect on quitting", "annotation_notes": ""}] |
Connected entities
Interventions
Conditions
Source
PMC3505846
A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults with Unipolar Depressive Disorders